



ASX & MEDIA RELEASE

4 SEPTEMBER 2018

INDEPENDENT RESEARCH VALIDATES SCIENCE AROUND MEDLAB'S NANOCELLE™

- Independent research from University of Sydney validates science around Medlab's NanoCelle™
- Research conducted with Medlab's cannabis medicines, NanaBis™ and NanaBidual™
- Results indicate tiny molecule components contain same properties and consistency

Australian medical life sciences company, Medlab Clinical Ltd (ASX: MDC), has received preliminary results from research conducted by the University of Sydney's Nano Institute, School of Pharmacy, to review its patented delivery platform, NanoCelle™.

NanoCelle™ delivers medicine in a tiny particle form in a spray to the buccal membrane (side) of the cheek with a view to improving ease of delivery along with the speed and rate of absorption into the bloodstream.

The University of Sydney research is a scientific characterisation project of NanoCelle™ which has been conducted using Medlab's cannabis-based medicines, NanaBis™ and NanaBidual™.

The research has concluded positively that molecules of the medicines, NanaBis™ (1:1 CBD:THC) and NanaBidual™ (18:2 CBD:THC), showed a consistent uniform pattern in nanoparticle form.

The type of work is critical as Medlab furthers its research endeavours for accepted, approved pharmaceuticals.

According to Medlab CEO, Dr Sean Hall, the NanoCelle™ platform was designed to bypass traditional routes of delivery such as the gastrointestinal/hepatic, ingested route.

"These results provide a significant level of confidence in Medlab's NanoCelle™ platform and further confirms specific proposed functions for Medlab's cannabis medicines. These results in conjunction with the early positive feedback from doctors prescribing NanaBis™ under the TGA's Special Access Scheme, gives Medlab great confidence in its NanoCelle™ research," Dr Sean Hall said.

Nanotechnology is the science and engineering of medicines at the nanometre scale or one-billionth of a metre. Medlab's NanoCelle™ platform is based on nanotechnology and is currently used in various Medlab medicines, including NanaBis™ and NanaBidual™.

Separately Medlab is conducting a clinical trial of NanoCelle™ with a widely used statin to validate speed of absorption into the bloodstream creating an ability to reduce the amount of dose and consequently have potential to reduce side effects.

Medlab has a licence to supply NanaBis™, with NanoCelle™, to prescribing doctors under the TGA's Special Access Scheme.

ISSUED FOR: MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co

FOR FURTHER INFORMATION: DR SEAN HALL, CEO, MEDLAB CLINICAL
TEL: +61 2 8203 9520, sean_hall@medlab.co

ISSUED BY: HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL
TEL +61 2 9286 1226 OR +61 468 960 457, marcha.vandenheuvel@hkstrategies.com

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, Nanocelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.